Measurement · healthcare · DACHJul 202610 min read360 words

Marketing attribution for Series B companies: scaling without breaking for healthcare and life sciences in the DACH region

How Series B companies scale marketing attribution across regions and teams without losing the discipline that made it work at Series A. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the DACH region.

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the DACH region. In this market, DACH buyers reward rigour, documentation, and long-cycle trust — not urgency-led campaigns, so the way you install marketing attribution has to be shaped to that reality from day one.

Series B is the stress test for marketing attribution. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.

The Series B move is to separate the model owner from the operators. One senior human owns strategy, attribution model reconciled to closed-won, and the weekly review; a small team runs the machine.

Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the DACH region it is compounded by the fact that trust-building cycle length, not intent is what actually gates growth. Marketing attribution is only useful here when it is pointed at both constraints at once.

Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.

The Series B failure mode of marketing attribution is picking a model to defend a budget instead of to learn, amplified by headcount. Fix the root cause; do not paper over it with more people.

Compensation begins to matter now. Pay operators on attribution model reconciled to closed-won outcomes, not on effort. Effort-based comp at Series B produces theatre.

A well-run marketing attribution function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.

Concretely for healthcare and life sciences in the DACH region: the healthcare teams that install this get past procurement instead of dying in it, and one properly-run DACH account survives leadership changes and compounds for years. That is the reason it is worth installing marketing attribution deliberately for this market rather than importing a playbook designed for somewhere else.

marketing attributionmulti-touch attributionself-reported attributionmarketing attribution for series Bscaling GTMmarketing attribution for healthcare and life sciencesmarketing attribution in the DACH regionhealthcare and life sciences growth in the DACH region

Frequently asked questions

Measurement · healthcare · DACH — answered

Does marketing attribution work for healthcare and life sciences in the DACH region?
Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the DACH region, DACH buyers reward rigour, documentation, and long-cycle trust — not urgency-led campaigns. The healthcare teams that install this get past procurement instead of dying in it.
How does marketing attribution change at Series B?
Ownership separates from execution; operating rhythm gets more deliberate; governance appears.
When should we expand to a second region?
After the first region delivers two straight quarters of defensible attribution model reconciled to closed-won.
What compensation model works for marketing attribution operators at Series B?
Outcome-linked on attribution model reconciled to closed-won, not activity-based.
What is the Series B stress point?
Picking a model to defend a budget instead of to learn, amplified by headcount. Fix the root, not the symptom.
What is the DACH-specific pitfall when running marketing attribution for healthcare?
Importing a playbook that was built for another market. In the DACH region, DACH buyers reward rigour, documentation, and long-cycle trust — not urgency-led campaigns — the install has to reflect that.

Growth Broker editorial

Filed under measurement · healthcare · dach

Up next

AI for Growth: the complete 2026 guide for B2B companies

Read piece

Ready to broker your growth?

Book a Growth Call